Category: Paxlovid

Government-Purchased COVID-19 Treatments Set to Run Out—Here’s What to Expect

COVID-19 vaccines and treatments that have been free of charge to consumers, due to U.S. government funding, will eventually transition to be provided via the regular health care system. This means that certain COVID-19 tests, vaccines, and treatments, will cost more for some. Here’s what it means for you: End of Emergency Ashish Jha, the…


Positive COVID Test Result No Longer Required to Prescribe Paxlovid, Lagevrio: FDA

Doctors and pharmacists can now prescribe COVID-19 drugs Paxlovid and Lagevrio to patients without a positive test of infection, the U.S. Food and Drug Administration (FDA) said Wednesday. Pfizer’s Paxlovid and Merck’s Lagevrio were granted emergency-use authorizations by the FDA in December 2021. Both oral pills have since been used as postinfection treatments for patients…


More Severe COVID-19 Wave to Hit China: Study

A breakneck pace and a lack of transparency are marking COVID-19’s spread to hundreds of millions of people in the world’s most populous nation. But how deadly will China’s virus surge get? Beijing said the virus wave has already passed its peak, and that the daily death rate has dropped over 70 percent. But a…


Canada Sought Help From U.S. on Paxlovid Use, Vaccination Messaging

Communication on COVID-19 between top public health officials in Canada and the U.S. has been limited, based on access to information records, but the few pieces of information released by the Canadian government show its chief public health officer leaning on her counterparts for advice. The Epoch Times filed an Access to Information (ATIP) request…


Canada Sought Help From US on Paxlovid Use, Vaccination Messaging

Communication on COVID-19 between top public health officials in Canada and the U.S. has been limited, based on access to information records, but the few pieces of information released by the Canadian government show its chief public health officer leaning on her counterparts for advice. The Epoch Times filed an Access to Information (ATIP) request…


Shanghai Hospitals Are Out of COVID Medicines

Shanghai continues to be challenged with surging COVID-19 infections. Patients are too numerous to be handled, and the infected face shortages of medicine. Many major hospitals in China have been fully occupied with severe cases, and doctors of community clinics and hospitals are overwhelmed with the number of patients. Staff at the Central Hospital of…


China is Concealing Real COVID-19 Death Toll to Save Face: Dr. Scott Atlas

A former White House Advisor said the Chinese Communist Party (CCP) is covering the truth of the COVID-19 situation in China for fear of its reputation being undermined. According to a Peking University study, the latest COVID-19 outbreak in China is estimated to have affected 900 million Chinese, with approximately 80 percent displaying severe symptoms….


Chinese People Turn to Indian-Made Generic Drugs After Pfizer’s Paxlovid Excluded from China’s Health Insurance

News Analysis Chinese people are searching for Indian-made generic drugs after Paxlovid, Pfizer’s COVID-19 antiviral drug, was recently excluded from China’s national health insurance scheme. On Jan. 8, China’s National Health Insurance Administration (NHSA) failed to negotiate with Pfizer to include Paxlovid in the national health insurance scheme on the grounds that Pfizer’s quote was…


Officials Say 88 Million People in China’s Henan Province Infected With COVID

Officials in China’s central province of Henan have said that the COVID-19 infection rate in the region was 89 percent, as the country battles a surge of infections and communist authorities continue to conceal the true death toll figures. Authorities in Henan, the country’s third most populous province, said at a Monday press conference that…


Pfizer’s Paxlovid Fails to Get in China’s National Insurance Policy

China’s National Healthcare Security Administration (NHSA) announced on Jan. 10 that it will not include Pfizer’s Paxlovid in its national reimbursement plan due to its high cost. The negotiation between China and Pfizer on Tuesday failed because Pfizer considered China “a middle-income country,” and the price proposed by Beijing was lower than what Pfizer would…